Altium Capital Management, LP, based in New York, NY, maintains an investment portfolio comprised of opportunistic growth companies in the healthcare sector. Recent reports on Altium’s first-year growth fund performance showcased returns of +28.0%. Compared to the S&P 500 during that same timeframe, the S&P only returned +3.51%. The XBI returned -17.8%, and the NBI returned -9.0% in the same time frame.
In the same June-December 2018 timeframe, Bloomberg reported Michael Gelband and Hyung Lee’s Exodus Point Capital’s multi-strategy fund performance at only +0.6%.
Altium Capital is led by Managing Partner and CIO Jacob Gottlieb MD, CFA and former Visium Asset Management founder and CIO (a hedge fund that had $8B in assets under management.) Gottlieb has a Doctorate of Medicine from New York University School of Medicine, a Bachelor of Arts in Economics from Brown University, a Chartered Financial Analyst certification from the Association for Investment Management and Research, and a P.R.M. designation from the Professional Risk Managers’ International Association. Altium invests in businesses with purposeful health and medical treatment advancements for a variety of diseases and chronic illnesses, including but not limited to diabetes, cancer and Alzheimer’s as well as other healthcare related businesses.
Performance gains that Altium has shown come by way of a rigorous research process to identify opportunities with growth businesses that “capitalize on pricing inefficiencies within the mid-cap sector and small cap”, Gottlieb has previously been quoted saying. One observer commented, “Gottlieb has always been an astute investor, so this performance is not surprising to me.”
Gottlieb is respected throughout the New York investment community. He is described as intelligent, affable and very supportive of people and organizations he believes in. He is also known as a dedicated business person who grew Visium to an $8 Billion dollar firm with over 175 people and offices in NY, San Francisco and London.
